Pilot Study of X-82 in Patients With Wet AMD

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD). Preliminary efficacy will be assessed by change from baseline in visual acuity, fluorescein leakage, retinal thickness and fibrosis, if detectable, based on fundus examination, fundus photography, fluorescein angiography and optical coherence tomography (OCT).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

X-82 to Treat Age-related Macular Degeneration

NCT02348359

TERMINATED PHASE2

Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD

NCT02543229

Eye Diseases Macular Degeneration Retinal Diseases +2 more

COMPLETED PHASE1

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

NCT01678963

Neovascular Age Related Macular Degeneration

COMPLETED PHASE2

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

NCT04832724

Neovascular Age-related Macular Degeneration Wet Macular Degeneration Wet Age-related Macular Degeneration

COMPLETED PHASE2

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

NCT06888492

NOT_YET_RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exudative Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

50 mg X-82 oral alternate days

50 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity develops

Group Type EXPERIMENTAL

X-82 oral

Intervention Type DRUG

X-82 oral for 24 weeks or until unacceptable toxicity develops

ranibizumab (Lucentis)

Intervention Type DRUG

Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

50 mg X-82 oral QD

50 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria.for 24 weeks or until unacceptable toxicity develops

Group Type EXPERIMENTAL

X-82 oral

Intervention Type DRUG

X-82 oral for 24 weeks or until unacceptable toxicity develops

ranibizumab (Lucentis)

Intervention Type DRUG

Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

100 mg X-82 oral alternate days

100 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria.for 24 weeks or until unacceptable toxicty develops

Group Type EXPERIMENTAL

X-82 oral

Intervention Type DRUG

X-82 oral for 24 weeks or until unacceptable toxicity develops

ranibizumab (Lucentis)

Intervention Type DRUG

Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

100 mg X-82 oral QD

100 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs

Group Type EXPERIMENTAL

X-82 oral

Intervention Type DRUG

X-82 oral for 24 weeks or until unacceptable toxicity develops

ranibizumab (Lucentis)

Intervention Type DRUG

Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

200 mg X-82 oral QD

200 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs

Group Type EXPERIMENTAL

X-82 oral

Intervention Type DRUG

X-82 oral for 24 weeks or until unacceptable toxicity develops

ranibizumab (Lucentis)

Intervention Type DRUG

Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

300 mg X-82 oral QD

300 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs.

Group Type EXPERIMENTAL

X-82 oral

Intervention Type DRUG

X-82 oral for 24 weeks or until unacceptable toxicity develops

ranibizumab (Lucentis)

Intervention Type DRUG

Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

X-82 oral

X-82 oral for 24 weeks or until unacceptable toxicity develops

Intervention Type DRUG

ranibizumab (Lucentis)

Rescue treatment with intravitreal ranibizumab (Lucentis) as needed

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Active choroidal neovascularization (CNV) associated with AMD, as evidenced on fluorescein angiography (FA) and OCT.
2. No previous treatment with anti-VEGF therapy or prior anti-VEGF therapy with evidence of response to treatment and the need for additional treatment.
3. Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA 20/32 to 20/320 in the study eye(s).
4. Adequate bone marrow function.
5. PT within the institutional upper limit of normal.
6. Adequate hepatic function.
7. Adequate renal function; serum creatinine.
8. Ability to swallow oral medication.
9. Age ≥ 50 years.
10. Willing and able to provide written informed consent, comply with the investigational study protocol and return for all study visits.

Exclusion Criteria

1. Previous treatment with photodynamic therapy (PDT) within 4 months of screening in the study eye.
2. CNV due to causes other than AMD.
3. Geographic atrophy involving the foveal center in the study eye.
4. Any retinal vascular disease or retinal degeneration other than AMD in the study eye.
5. In the opinion of the investigator, any significant disease in the study eye that could compromise best-corrected visual acuity.
6. Cataract surgery in the study eye within three months of screening.
7. Trabeculectomy or aqueous shunt or valve in the study eye.
8. Intraocular surgery in the study eye within three months of screening; Nd:YAG capsulotomy or laser iridotomy within 30 days of screening.
9. Inadequate pupillary dilation or significant media opacities in the study eye.
10. Use of any investigational agent or participation in any other clinical trial of an investigational agent or investigational therapy within thirty (30) days of baseline with the exception of subjects who are participating in the AREDS2 study.
11. Females of child bearing potential that are pregnant or not using medically acceptable contraception; males unwilling to take adequate contraceptive measures. Females that are breastfeeding are also excluded.
12. Serious allergy to or prior significant adverse reaction to fluorescein.
13. Undiagnosed acute illness first observed during screening or between screening and baseline, or severe concurrent medical conditions that, in the investigators judgment, represent a safety concern.
14. Severe cardiac disease, symptomatic congestive heart failure, unstable angina, acute coronary syndrome, myocardial infarction or coronary artery revascularization, or arterial thrombosis within 12 months of start of study drug, inadequately controlled hypertension, or ventricular tachyarrhythmias requiring ongoing treatment.
15. QTc ≥450 msec or subjects with a history of risk factors for Torsades de Pointes or other clinically significant ECG abnormalities as determined by the investigator.
16. Stroke or transient ischemic attack within 12 months of trial entry.
17. Clinically significant impaired renal or hepatic function.
18. Any major surgical procedure within one month of trial entry.
19. Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-82.
20. Receiving treatment with anti-coagulants other than 325 mg of aspirin per day.
21. Serious active infection, other serious medical condition or any other condition that would impair the ability of the subject to administer the investigational drug or to adhere to the study protocol requirements.
22. Presence of any condition which, in the judgment of the investigator, would prevent the subject from completing the study.
23. No herbal medications with the exception of bilberry are allowed within 7 days of start of study drug.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No